Vivien Bonert1, John Carmichael2, Zengru Wu3, James Mirocha2, Daniel A Perez2, Nigel J Clarke3, Richard E Reitz3, Michael J McPhaul3, Adam Mamelak2. 1. Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Advanced Health Sciences Pavilion, Sixth Floor, A6600, Los Angeles, CA, 90048, USA. Vivien.Bonert@cshs.org. 2. Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Advanced Health Sciences Pavilion, Sixth Floor, A6600, Los Angeles, CA, 90048, USA. 3. Quest Diagnostics, Inc., San Juan Capistrano, CA, 92675, USA.
Abstract
PURPOSE: Measuring IGF-1, a biomarker for GH activity, is critical to evaluating disordered hypothalamic-pituitary GH axis. Inconsistent IGF-1 measurements among different immunoassays are well documented. We switched from Immulite 2000 immunoassay to narrow-mass-extraction, high-resolution liquid chromatography mass-spectrometry (LC-MS) compliant with recent consensus recommendations on assay standardization. Comparability of these two assays in patients with pituitary disease in a clinical practice setting is not known. We sought to compare IGF-1 levels on Immulite 2000 and LC-MS in samples from naïve and treated patients with secretory and non-secretory pituitary masses. METHODS: We prospectively collected serum samples from 101 patients treated at the Cedars-Sinai Pituitary Center between February 2012 and March 2014. We intentionally recruited more patients with acromegaly or GH deficiency to ensure a clinically representative cohort. Samples were classified as in or out of the respective reference ranges. Bland-Altman analysis was used to assess agreement between assays. RESULTS: Twenty-four percent of samples were classified differently as below, in, or above range. Agreement between the assays was poor overall, with a significant bias for immunoassay reporting higher values than LC-MS. This pattern was also observed in patients with acromegaly and those with ≥ 2 pituitary hormone deficiencies. CONCLUSIONS: IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.
PURPOSE: Measuring IGF-1, a biomarker for GH activity, is critical to evaluating disordered hypothalamic-pituitary GH axis. Inconsistent IGF-1 measurements among different immunoassays are well documented. We switched from Immulite 2000 immunoassay to narrow-mass-extraction, high-resolution liquid chromatography mass-spectrometry (LC-MS) compliant with recent consensus recommendations on assay standardization. Comparability of these two assays in patients with pituitary disease in a clinical practice setting is not known. We sought to compare IGF-1 levels on Immulite 2000 and LC-MS in samples from naïve and treated patients with secretory and non-secretory pituitary masses. METHODS: We prospectively collected serum samples from 101 patients treated at the Cedars-Sinai Pituitary Center between February 2012 and March 2014. We intentionally recruited more patients with acromegaly or GH deficiency to ensure a clinically representative cohort. Samples were classified as in or out of the respective reference ranges. Bland-Altman analysis was used to assess agreement between assays. RESULTS: Twenty-four percent of samples were classified differently as below, in, or above range. Agreement between the assays was poor overall, with a significant bias for immunoassay reporting higher values than LC-MS. This pattern was also observed in patients with acromegaly and those with ≥ 2 pituitary hormone deficiencies. CONCLUSIONS:IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.
Entities:
Keywords:
Immunoassay; Insulin-like growth factor; Mass spectrometry; Pituitary disease
Authors: Kevin C J Yuen; Nicholas A Tritos; Susan L Samson; Andrew R Hoffman; Laurence Katznelson Journal: Endocr Pract Date: 2016-07-13 Impact factor: 3.443
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06 Impact factor: 5.958
Authors: A J Varewijck; S W J Lamberts; A J van der Lely; S J C M M Neggers; L J Hofland; J A M J L Janssen Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Maria Luisa Granada; Angels Ulied; Felipe F Casanueva; Antonio Pico; Tomas Lucas; Elena Torres; Anna Sanmartí Journal: Clin Endocrinol (Oxf) Date: 2007-11-02 Impact factor: 3.478
Authors: Frank Klont; Lyanne M Kieneker; Antonio W Gomes-Neto; Suzanne P Stam; Nick H T Ten Hacken; Ido P Kema; André P van Beek; Else van den Berg; Péter Horvatovich; Rainer Bischoff; Stephan J L Bakker Journal: J Clin Med Date: 2020-01-21 Impact factor: 4.241